Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2022 | How risk assessment in myeloma is changing with the emergence of MRD

Mattia D'Agostino • 12 May 2022
COMy 2022
Multiple Myeloma

Mattia D’Agostino, MD, University of Turin, Turin, Italy, briefly discusses advances that have been made in the tools used to define risk in multiple myeloma, drawing focus on measurable residual disease (MRD), and how these novel prognostic tools may benefit patients in the future. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Mattia D'Agostino

Understanding the biology of t(4;14) myeloma: genomics, transcriptomics, and epigenomics 1:12
Understanding the biology of t(4;14) myeloma: genomics, transcriptomics, and epigenomics
Mattia D'Agostino • 23 Oct 2025
Improving outcomes for patients with t(4;14) myeloma: selectively targeting NSD2 1:21
Improving outcomes for patients with t(4;14) myeloma: selectively targeting NSD2
Mattia D'Agostino • 23 Oct 2025
Translocation 4;14 in multiple myeloma: is it truly a marker of high-risk disease? 1:23
Translocation 4;14 in multiple myeloma: is it truly a marker of high-risk disease?
Mattia D'Agostino • 23 Oct 2025
The clinical significance of translocation 4;14 in multiple myeloma 0:52
The clinical significance of translocation 4;14 in multiple myeloma
Mattia D'Agostino • 23 Oct 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals